Puma Biotechnology | PBYI - Resultado Líquido





Resultado Líquido Alterar Data
Agios Pharmaceuticals USD -108.04M 4.61M 2025-12
Alnylam Pharmaceuticals USD 186.42M 64.66M 2025-12
Amgen USD 1.33B 1.88B 2025-12
Biogen USD 466.5M 168.3M 2025-09
BioMarin Pharmaceutical USD -46.57M 15.83M 2025-12
Daiichi Sankyo JPY 86.63B 41.32B 2025-12
Esperion Therapeutics USD 61.83M 93.16M 2025-12
Exelixis USD 193.58M 8.73M 2025-09
Gilead Sciences USD 2.18B 869M 2025-12
Glaxosmithkline GBP 846.06M 1.87B 2025-12
Incyte USD 299.28M 124.89M 2025-12
MacroGenics USD -14.16M 30.98M 2025-12
Moderna USD -200M 625M 2025-09
Novartis USD 2.41B 1.52B 2025-12
Pfizer USD -1.65B 5.19B 2025-12
PTC Therapeutics USD -134.96M 150.86M 2025-12
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 844.6M 615.4M 2025-12
Roche Holding CHF 5.47B 1.76B 2025-12
Sangamo BioSciences USD -36.13M 12.96M 2024-06
Sarepta Therapeutics USD -412.23M 232.28M 2025-12
Takeda JPY 103.64B 115.44B 2025-12
TG Therapeutics USD 23.04M 367.86M 2025-12
Ultragenyx Pharmaceutical USD -129M 51.41M 2025-12
Vanda Pharmaceuticals USD -18.9M 13.58M 2024-12
Vertex Pharmaceuticals USD 1.19B 108.2M 2025-12